DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2qqr4k/savella_major) has announced the addition of the "Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Savella (minlacipran) is an SNRI indicated for the treatment of depression, but only in Japan. Savella is available in the US, but is only indicated for the treatment of fibromyalgia. Savella has not been granted marketing approval by the European Medicine Agency (EMA) for any indication, but it is available in France for the treatment of MDD. It was initially developed by Cypress Bioscience, which was later wholly acquired by Royalty Pharma.
- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Savella including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Savella for the top three countries from 2013 to 2023.
Sales information covered for the US, France and Japan.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Savella (Milnacipran)
For more information visit http://www.researchandmarkets.com/research/2qqr4k/savella_major